Expression of prion protein is closely associated with pathological and clinical progression and abnormalities of p53 in head and neck squamous cell carcinomas

Wei,Wei; Shi,Qi; Zhang,Nai-Song; Xiao,Kang; Chen,Li-Na; Yang,Xiao‑Dong; Ji,Jia-Fu; Dong,Xiao-Ping

doi:10.3892/or.2015.4425

Expression of prion protein is closely associated with pathological and clinical progression and abnormalities of p53 in head and neck squamous cell carcinomas

Authors:
- Wei Wei
- Qi Shi
- Nai-Song Zhang
- Kang Xiao
- Li-Na Chen
- Xiao‑Dong Yang
- Jia-Fu Ji
- Xiao-Ping Dong
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Chinese Ministry of Education), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhejiang University, Hangzhou 310003), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, P.R. China
Published online on: November 16, 2015 https://doi.org/10.3892/or.2015.4425
Pages: 817-824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prion protein (PrP) is a glycosyl-phosphatidylinositol (GPI)-anchored membrane protein that functions as a unique pathogenic agent in transmissible spongiform encephalopathy (TSE). In the past decade, overexpression of PrP was observed in a number of human malignant tumors, such as gastric, breast and pancreatic cancer. However, the role of PrP expression in squamous cell carcinoma is rarely documented. To screen PrP expression in head and neck squamous cell carcinoma (HNSCCs), the paraffin-embedded specimens of 92 pathologically diagnosed HNSCCs were assessed by PrP-specific immunohistochemistry (IHC). A total of 55.43% (51/92) of the tested carcinoma tissues were PrP-positive. The rate of positivity and the staining intensity of PrP were closely related with the pathological degree of the HNSCCs; a higher rate of PrP expression was noted in the group of poorly differentiated cancers. PrP-positivity rates increased along with the progression of the clinical grade of the carcinomas. Further evaluation of the associations between PrP expression and the data concerning p53 abnormalities and human papillomavirus (HPV) infection in these samples as previously described, revealed that PrP-positive staining was more frequently detected in the tissues with p53-positive accumulation and the wild-type TP53 gene. The patients with a proline (Pro) polymorphism in SNP72 of TP53 showed significantly higher PrP-positive rates than those with arginine (Arg). No notable difference in PrP expression was identified between the HPV-positive and HPV-negative group. These data indicate a close association of PrP expression with clinical and histological differentiation of HNSCCs, as well as abnormalities of p53.

View Figures

View References

1	Inglehart RC, Scanlon CS and D'Silva NJ: Reviewing and reconsidering invasion assays in head and neck cancer. Oral Oncol. 50:1137–1143. 2014. View Article : Google Scholar : PubMed/NCBI
2	Machiels JP, Lambrecht M, Hanin FX, Duprez T, Gregoire V, Schmitz S and Hamoir M: Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep. 6:442014. View Article : Google Scholar : PubMed/NCBI
3	Kaba G, Dzudzor B, Gyasi RK, Asmah RH, Brown CA, Kudzi W and Wiredu EK: Human papillomavirus genotypes in a subset of head and neck squamous cell carcinoma. West Afr J Med. 33:121–124. 2014.PubMed/NCBI
4	Woods R Sr, O'Regan EM, Kennedy S, Martin C, O'Leary JJ and Timon C: Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World J Clin Cases. 2:172–193. 2014.PubMed/NCBI
5	Dang M, Lysack JT, Wu T, Matthews TW, Chandarana SP, Brockton NT, Bose P, Bansal G, Cheng H, Mitchell JR, et al: MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol. 36:166–170. 2015. View Article : Google Scholar
6	Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, Takenaka Y, Nakahara S, Todo T, Hongyo T, et al: Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci. 105:409–417. 2014. View Article : Google Scholar : PubMed/NCBI
7	Shi Q, Xiao K, Wei W, Zhang BY, Chen C, Xu Y, Chen LN, Song YT, Ma X, Zhang NS, et al: Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients. Oncol Rep. 30:2811–2819. 2013.PubMed/NCBI
8	Colby DW and Prusiner SB: Prions. Cold Spring Harb Perspect Biol. 3:a0068332011. View Article : Google Scholar : PubMed/NCBI
9	Liberski PP: Historical overview of prion diseases: A view from afar. Folia Neuropathol. 50:1–12. 2012.PubMed/NCBI
10	Gasperini L and Legname G: Prion protein and aging. Front Cell Dev Biol. 2:442014. View Article : Google Scholar : PubMed/NCBI
11	Llorens F, Ferrer I and del Río JA: Gene expression resulting from PrP^C ablation and PrP^C overexpression in murine and cellular models. Mol Neurobiol. 49:413–423. 2014. View Article : Google Scholar
12	Yusa S, Oliveira-Martins JB, Sugita-Konishi Y and Kikuchi Y: Cellular prion protein: From physiology to pathology. Viruses. 4:3109–3131. 2012. View Article : Google Scholar : PubMed/NCBI
13	He M, Wang L, Pu J, Yang Q, Li G and Hao J: Proliferin-related protein overexpression in SGC-7901 gastric cancer cells inhibits in vitro cell growth and tumorigenesis in nude mice. Oncol Rep. 29:2243–2248. 2013.PubMed/NCBI
14	Sy MS, Altekruse SF, Li C, Lynch CF, Goodman MT, Hernandez BY, Zhou L, Saber MS, Hewitt SM and Xin W: Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository. Cancer Biomark. 10:251–258. 2011–2012.
15	Farah J, Sayah R, Martinetti F, Donadille L, Lacoste V, Hérault J, Delacroix S, Nauraye C, Vabre I, Lee C, et al: Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma. Radiat Prot Dosimetry. 161:363–367. 2014. View Article : Google Scholar
16	Antony H, Wiegmans AP, Wei MQ, Chernoff YO, Khanna KK and Munn AL: Potential roles for prions and protein-only inheritance in cancer. Cancer Metastasis Rev. 31:1–19. 2012. View Article : Google Scholar :
17	Hinton C, Antony H, Hashimi SM, Munn A and Wei MQ: Significance of prion and prion-like proteins in cancer development, progression and multi-drug resistance. Curr Cancer Drug Targets. 13:895–904. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wei W, Shi Q, Guo F, Zhang BY, Chen C, Zhang NS and Dong XP: The distribution of human papillomavirus in tissues from patients with head and neck squamous cell carcinoma. Oncol Rep. 28:1750–1756. 2012.PubMed/NCBI
19	Gao JM, Gao C, Han J, Zhou XB, Xiao XL, Zhang J, Chen L, Zhang BY, Hong T and Dong XP: Dynamic analyses of PrP and PrP^Sc in brain tissues of golden hamsters infected with scrapie strain 263K revealed various PrP forms. Biomed environ Sci. 17:8–20. 2004.PubMed/NCBI
20	Zhang J, Chen L, Zhang BY, Han J, Xiao XL, Tian HY, Li BL, Gao C, Gao JM, Zhou XB, et al: Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263K in different challenging pathways. Biomed Environ Sci. 17:65–78. 2004.PubMed/NCBI
21	Antonacopoulou AG, Palli M, Marousi S, Dimitrakopoulos FI, Kyriakopoulou U, Tsamandas AC, Scopa CD, Papavassiliou AG and Kalofonos HP: Prion protein expression and the M129V polymorphism of the PRNP gene in patients with colorectal cancer. Mol Carcinog. 49:693–699. 2010.PubMed/NCBI
22	Duhayon S, Hoet P, Van Maele-Fabry G and Lison D: Carcinogenic potential of formaldehyde in occupational settings: A critical assessment and possible impact on occupational exposure levels. Int Arch Occup Environ Health. 81:695–710. 2008. View Article : Google Scholar
23	Pan Y, Zhao L, Liang J, Liu J, Shi Y, Liu N, Zhang G, Jin H, Gao J, Xie H, et al: Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J. 20:1886–1888. 2006. View Article : Google Scholar : PubMed/NCBI
24	Meslin F, Conforti R, Mazouni C, Morel N, Tomasic G, Drusch F, Yacoub M, Sabourin JC, Grassi J, Delaloge S, et al: Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. Ann Oncol. 18:1793–1798. 2007. View Article : Google Scholar : PubMed/NCBI
25	Liang J, Pan YL, Ning XX, Sun LJ, Lan M, Hong L, Du JP, Liu N, Liu CJ, Qiao TD, et al: Overexpression of PrP^C and its antiapoptosis function in gastric cancer. Tumour Biol. 27:84–91. 2006. View Article : Google Scholar
26	Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, Singh N, Tartakoff A, Abbott DW, Xin W, et al: Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest. 119:2725–2736. 2009. View Article : Google Scholar : PubMed/NCBI
27	Sy MS, Li C, Yu S and Xin W: The fatal attraction between pro-prion and filamin A: Prion as a marker in human cancers. Biomarkers Med. 4:453–464. 2010. View Article : Google Scholar
28	Sauer H, Dagdanova A, Hescheler J and Wartenberg M: Redox-regulation of intrinsic prion expression in multicellular prostate tumor spheroids. Free Radic Biol Med. 27:1276–1283. 1999. View Article : Google Scholar
29	Zhang J, Zeng Y, Zheng J and Xu J: Expression of Prion protein and its clinical significance in oral squamous cells carcinoma and oral leukoplakia. Zhonghua Kou Qiang Yi Xue Za Zhi. 48:752–754. 2013.In Chinese.
30	Wang JH, Du JP, Zhang YH, Zhao XJ, Fan RY, Wang ZH, Wu ZT and Han Y: Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol. 17:3986–3993. 2011. View Article : Google Scholar : PubMed/NCBI
31	Courtney R and Ranganathan S: Simultaneous adrenocortical carcinoma and neuroblastoma in an infant with a novel germline p53 mutation. J Pediatr Hematol Oncol. 37:215–218. 2015. View Article : Google Scholar
32	Seema R, Parul S, Nita K and Kamlesh: High-risk histomorphological features in retinoblastoma and their association with p53 expression: An Indian experience. Indian J Ophthalmol. 62:1069–1071. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li ZD, Wang K, Yang XW, Zhuang ZG, Wang JJ and Tong XW: Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer. Int J Clin Exp Pathol. 7:7931–7937. 2014.
34	Read ML, Seed RI, Modasia B, Kwan PP, Sharma N, Smith VE, Watkins RJ, Bansal S, Gagliano T, Stratford AL, et al: The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer. Mol Carcinog. Nov 18–2014.Epub ahead of print. PubMed/NCBI
35	Silva JL, De Moura Gallo CV, Costa DC and Rangel LP: Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci. 39:260–267. 2014. View Article : Google Scholar : PubMed/NCBI
36	Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T and Aboussekhra A: The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett. 3:875–878. 2012.PubMed/NCBI
37	Zaravinos A: An updated overview of HPV-associated head and neck carcinomas. Oncotarget. 5:3956–3969. 2014. View Article : Google Scholar : PubMed/NCBI
38	Petit CS, Besnier L, Morel E, Rousset M and Thenet S: Roles of the cellular prion protein in the regulation of cell-cell junctions and barrier function. Tissue Barriers. 1:e243772013. View Article : Google Scholar
39	Roucou X: Regulation of PrP^C signaling and processing by dimerization. Front Cell Dev Biol. 2:572014. View Article : Google Scholar
40	Martin-Lannerée S, Hirsch TZ, Hernandez-Rapp J, Halliez S, Vilotte JL, Launay JM and Mouillet-Richard S: PrP^C from stem cells to cancer. Front Cell Dev Biol. 2:552014.
41	Cheng Y, Li Y, Liu D, Zhang R and Zhang J: miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway. FEBS Lett. 588:3274–3281. 2014. View Article : Google Scholar : PubMed/NCBI
42	Xue P, Yang X, Liu Y, Xiong C and Ruan J: A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells. Biomed Pharmacother. 68:1049–1056. 2014. View Article : Google Scholar : PubMed/NCBI